Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 2
1997 5
1998 10
1999 20
2000 9
2001 6
2002 5
2003 7
2004 8
2005 12
2006 10
2007 17
2008 18
2009 17
2010 19
2011 30
2012 37
2013 30
2014 34
2015 38
2016 39
2017 45
2018 47
2019 44
2020 52
2021 54
2022 29
Text availability
Article attribute
Article type
Publication date

Search Results

571 results
Results by year
Filters applied: . Clear all
Page 1
Lung Cancer Biomarkers.
Villalobos P, Wistuba II. Villalobos P, et al. Among authors: wistuba ii. Hematol Oncol Clin North Am. 2017 Feb;31(1):13-29. doi: 10.1016/j.hoc.2016.08.006. Hematol Oncol Clin North Am. 2017. PMID: 27912828 Free PMC article. Review.
Diagnosis and Molecular Classification of Lung Cancer.
Rodriguez-Canales J, Parra-Cuentas E, Wistuba II. Rodriguez-Canales J, et al. Among authors: wistuba ii. Cancer Treat Res. 2016;170:25-46. doi: 10.1007/978-3-319-40389-2_2. Cancer Treat Res. 2016. PMID: 27535388 Review.
PD-L1 as a biomarker of response to immune-checkpoint inhibitors.
Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, Wistuba II, Rimm DL, Tsao MS, Hirsch FR. Doroshow DB, et al. Among authors: wistuba ii. Nat Rev Clin Oncol. 2021 Jun;18(6):345-362. doi: 10.1038/s41571-021-00473-5. Epub 2021 Feb 12. Nat Rev Clin Oncol. 2021. PMID: 33580222 Review.
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.
Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco SE, Gay L, Ali SM, Elvin JA, Singal G, Ross JS, Fabrizio D, Szabo PM, Chang H, Sasson A, Srinivasan S, Kirov S, Szustakowski J, Vitazka P, Edwards R, Bufill JA, Sharma N, Ou SI, Peled N, Spigel DR, Rizvi H, Aguilar EJ, Carter BW, Erasmus J, Halpenny DF, Plodkowski AJ, Long NM, Nishino M, Denning WL, Galan-Cobo A, Hamdi H, Hirz T, Tong P, Wang J, Rodriguez-Canales J, Villalobos PA, Parra ER, Kalhor N, Sholl LM, Sauter JL, Jungbluth AA, Mino-Kenudson M, Azimi R, Elamin YY, Zhang J, Leonardi GC, Jiang F, Wong KK, Lee JJ, Papadimitrakopoulou VA, Wistuba II, Miller VA, Frampton GM, Wolchok JD, Shaw AT, Jänne PA, Stephens PJ, Rudin CM, Geese WJ, Albacker LA, Heymach JV. Skoulidis F, et al. Among authors: wistuba ii. Cancer Discov. 2018 Jul;8(7):822-835. doi: 10.1158/2159-8290.CD-18-0099. Epub 2018 May 17. Cancer Discov. 2018. PMID: 29773717 Free PMC article. Clinical Trial.
Pathology and Classification of SCLC.
Raso MG, Bota-Rabassedas N, Wistuba II. Raso MG, et al. Among authors: wistuba ii. Cancers (Basel). 2021 Feb 16;13(4):820. doi: 10.3390/cancers13040820. Cancers (Basel). 2021. PMID: 33669241 Free PMC article. Review.
Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.
Sen T, Rodriguez BL, Chen L, Corte CMD, Morikawa N, Fujimoto J, Cristea S, Nguyen T, Diao L, Li L, Fan Y, Yang Y, Wang J, Glisson BS, Wistuba II, Sage J, Heymach JV, Gibbons DL, Byers LA. Sen T, et al. Among authors: wistuba ii. Cancer Discov. 2019 May;9(5):646-661. doi: 10.1158/2159-8290.CD-18-1020. Epub 2019 Feb 18. Cancer Discov. 2019. PMID: 30777870 Free PMC article.
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.
Cascone T, William WN Jr, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, Khan MAW, Dejima H, Francisco-Cruz A, Parra ER, Solis LM, Fujimoto J, Tran HT, Kalhor N, Fossella FV, Mott FE, Tsao AS, Blumenschein G Jr, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Antonoff MB, Kadara H, Haymaker C, Bernatchez C, Ajami NJ, Jenq RR, Sharma P, Allison JP, Futreal A, Wargo JA, Wistuba II, Swisher SG, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Sepesi B. Cascone T, et al. Among authors: wistuba ii. Nat Med. 2021 Mar;27(3):504-514. doi: 10.1038/s41591-020-01224-2. Epub 2021 Feb 18. Nat Med. 2021. PMID: 33603241 Free PMC article. Clinical Trial.
Resolving the Spatial and Cellular Architecture of Lung Adenocarcinoma by Multiregion Single-Cell Sequencing.
Sinjab A, Han G, Treekitkarnmongkol W, Hara K, Brennan PM, Dang M, Hao D, Wang R, Dai E, Dejima H, Zhang J, Bogatenkova E, Sanchez-Espiridion B, Chang K, Little DR, Bazzi S, Tran LM, Krysan K, Behrens C, Duose DY, Parra ER, Raso MG, Solis LM, Fukuoka J, Zhang J, Sepesi B, Cascone T, Byers LA, Gibbons DL, Chen J, Moghaddam SJ, Ostrin EJ, Rosen D, Heymach JV, Scheet P, Dubinett SM, Fujimoto J, Wistuba II, Stevenson CS, Spira A, Wang L, Kadara H. Sinjab A, et al. Among authors: wistuba ii. Cancer Discov. 2021 Oct;11(10):2506-2523. doi: 10.1158/2159-8290.CD-20-1285. Epub 2021 May 10. Cancer Discov. 2021. PMID: 33972311 Free PMC article.
Multiplex Immunofluorescence Assays.
Francisco-Cruz A, Parra ER, Tetzlaff MT, Wistuba II. Francisco-Cruz A, et al. Among authors: wistuba ii. Methods Mol Biol. 2020;2055:467-495. doi: 10.1007/978-1-4939-9773-2_22. Methods Mol Biol. 2020. PMID: 31502166 Review.
NSD2 dimethylation at H3K36 promotes lung adenocarcinoma pathogenesis.
Sengupta D, Zeng L, Li Y, Hausmann S, Ghosh D, Yuan G, Nguyen TN, Lyu R, Caporicci M, Morales Benitez A, Coles GL, Kharchenko V, Czaban I, Azhibek D, Fischle W, Jaremko M, Wistuba II, Sage J, Jaremko Ł, Li W, Mazur PK, Gozani O. Sengupta D, et al. Among authors: wistuba ii. Mol Cell. 2021 Nov 4;81(21):4481-4492.e9. doi: 10.1016/j.molcel.2021.08.034. Epub 2021 Sep 22. Mol Cell. 2021. PMID: 34555356
571 results